<DOC>
	<DOCNO>NCT00073541</DOCNO>
	<brief_summary>EMD 72000 experimental , biological drug . Studies animal indicate EMD 72000 block factor find surface many cancer cell . The factor call epidermal growth factor receptor EGFR . One type cancer frequently contain EGFR ovarian cancer . This study test safety effect EMD 72000 subject EGFR-positive recurrent ovarian cancer follow standard treatment fail .</brief_summary>
	<brief_title>A Study Safety Effects EMD 72000 Subjects With Recurrent Ovarian Cancer</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<criteria>Recurrent ovarian cancer ( include primary peritoneal cancer ) follow treatment ( e.g. , doxorubicin HCL liposome , topotecan , etc . ) primary secondary platinumrefractory disease Immunohistochemical evidence tumor EGFR ( HER1 ) expression At least one measurable lesion accord WHO criteria Life expectancy ≥ 12 week ECOG performance status 01 History prior MAb therapy History prior treatment EGFR ( HER1 ) direct therapy Known brain metastasis Presence ≥ Grade 2 preexist skin disorder ( alopecia permit ) Known intercurrent infection immunosuppression Actively infect , chronic carrier HBV Evidence HCV disease Previous diagnosis autoimmune disease Known hypersensitivity administer drug component Receipt chemotherapy , radiation therapy , another investigational drug within 30 day enrollment</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>EGFR ; HER-1 ; monoclonal antibody ; target therapy</keyword>
</DOC>